|Signal Transduction Education
|Active Learning Projects - Gleevec Project - Description
active learning, any time, any place and anywhere
Objective: learn biology through Web-based tools and annotated databases
Description of the projet BCP608 "Gleevec"
You are about to start a group-based student project which constitutes the active learning part of the teaching module BCP608 "Signalisation Cellulaire" of Pr IJsbrand Kramer. It is about the development of a website, in french, that deals with the novel anticancer drug Gleevec (Glivec or Imatinib) and its use in the treatment of chronic myeloid leukemia. The website should deal with different aspects of the disease and its treatment and present the subject at different levels of complexity. Its main content must be intelligible for anyone with five years of secondary education but, depending on the subject concerned, it shoud also contain information that is instructive to health care professionals and scientists.
The projet has two aims:
- to learn to translate the knowledge and skills you have acquired during the cellular signal transduction course, into a richly illustrated and highly informative website that covers a broad spectrum of subjects dealing with cancer and its treatment
- to make available to society, by means of novel information and communication technology, the fruits of your acquired skills and knowledge.
Groups and their subjects
- Pathology of chronic myeloid leukemia - Audrey Dupin, Emmanuel Dupuy, Aurélie Lefevre, Amandine Saulnier
- Etiology/cytogenetics of chronic myeloid leukemia - Rémi Laporte, Karim Mansoury, Aurore Trocolie, Bachir Kantana
- General principles of signal transduction - Paptiste Coutaud, Julien Gibon, Julie Janvore, Nadia Chouaïb
- Development of gleevec and its mode of action - Pierre Alexis Cayatte, Paul Lesbats, Phuong-Hoang Nguyen, Diane Thibon
- Treatment of chronic myeloid leukemia - Anne-Sophie Godeaux, Charlotte Lalande, Mercé Amandine, Anne-Gaëlle Audouys
- All members search for interesting websites about Gleevec (search for Gleevec, Glivec or Imatinib) and chronic myelogenous leukemia or leucémie chronique myeloide, in order to get a general impression of the disease and its treatment and how the subject has been presented (text and images). After you have visitied these websites, ask yourself the following questions: why was the site informative or not informative, how was the navigation within the site; intuitive or not at all? Were lots of explanations missing? What did the figures look like? What resolution did they have? br>
- Then focus on your specific group subjet, but this time search for scientific articles in PubMed. Those working on pathology, etiology and cytogenetics might find a lot of information in the OMIM, those working on molecular mechanism should consult articles, find protein structures in PDB, they should check Expasy/Swiss Prot and download Pymol in order to make professional presentation of these structures. They should also read "an introduction to protein structure by Brandon & Tooze (Garland press). Explore the many excellent annotated databases on the web. For those working on the general principles of signal transduction, check "Signal Transduction" (Gomperts, Kramer, Tatham) in the library. For the pathology, a general textbook on pathology , medical websites or even Wikipedia may be good sources to find and understand the clinical terminology. Do include an explanation of the symptoms of the disease.
- As soon as you have ideas or important information, start writing on the Twiki platform (see instructions below). You can start by dividing the page in a number of sections, one for each author, you could use different colours of the font to indicate your contribution, you could ask questions about the text of others. Later in the process you modify the presentation. It is important not to wait untill the last minute. Start writing, get your thoughts on paper as soon as you have made your first investigations. Write keywords down.
- Figures: it is very important to make good figures supporting your text. For instance structural images of c-Abl and its inhibitor, images of blood cell composition in healthy people and patients with leukemia, an image of the process of heamatopoiesis, of chromosome translocation, genefusion products etc. If you include clinical pictures, please mask the identity of the person.
- Figure format: Make figures on any platforme (examples Photoshop, Coreldraw, PowerPoint) but save them in the end in a JPEG format ("export" function of "save for the Web" function), with a resolution of 100 pixels/inch (pouce) and not bigger then 175 Kb (Ko) . To insert a figure, you first would need to know the exact location of the picture on your computer. It is best to create a TWIKI folder (dossier) on your C: drive, otherwise you get very lenghty instructions. For example, C:\TWIKI\. Then you click on the "mountain onglet" in the "outils bar" above and you type the placement of the picture or you paste (coller) the information of the notepad at the "image URL" but this time you also add the name of the image (in this example in green) : C:\TWIKI\figure-1.jpg.
For certain images it may be better to link them to the website. You can either put a very small icon version in the webpage and link the icon or you make a text referal like; click here for a detailed image of the structure of c-Abl. You first will need to attach the image by using the "attach" command at the top of the page (next to the Edit command). You then proceed exactly as for the insertion of an image (see above). In this example the image is "figure2.png". To create the link highlight the icon or text and you either click on the right hand mouse button or on the link icon in the edit bar above (image d'une chaine). When the textbox appear you add "%ATTACHURL%/figure2.png" and in the "target" box you select "new window (blank)" (see image below). You can add a title such as "c-Abl structure".
- Respect copyright: make original figures but if you want to incorporate existing pictures, search for the authors and check their copyrights. Ask for permission if necessary. In all cases, even for adaptations of tables and figures, mention the original source: author plus website (URL), article or book from where you took the information. Acknowledge Protein Database (PDB), Pymol (or other programme) or a clinician that you consulted.
- You can cross reference to existing websites but make sure that the subject is relevant and that the reader knows what to expect. Always make clear that you link to other resources : no silent links.
- Write important (historical) references (make a selection) at the bottom of the page.
- Keep a backup of all your work (create a folder (dossier) on your harddisk, external disk, distribute to members or put it on a memostick (clé USB). "I lost all information" is not a valid argument for not having submitted the webpage!!!
Click on the relevant page at the top of these instructions ( i.e. groupe 1 "pathology" clicks on "groupe 1") , then click on "edit", type the identifier and the password that you have been sent by email and start writing your text! Do not forget to save when you are ready (and save whilst working). All members of the group have access to their page and they can modify the page at anytime, anywhere and anyplace (with access to internet). You can modify entries of other members of your groupe, or place important information into their section! The editor of the group is responsable for the coordination of the final version of the document.
Chaque membre de l'équipe attribuera à lui meme et à chacun de ses co-équipiers une mention de "satisfaction" concernant la participation au travail commun (mauvais (coefficient 0.3), moyen (coefficient 0.6) ou satisfaisant (coefficient 1.0). L'editeur de l'équipe envoi le tableau de coefficients avant 27 avril 2006 à email@example.com
La note individuelle du projet est calculée comme suite : note de l'équipe x moyenne du coefficient de participation.
Ceux/celles qui contesteraient leur coefficient de participation devront prendre contact avec firstname.lastname@example.org. Un entretien de 15 sera fixé. Au cours de cet entretien vous exposerez oralement, à l'aide de schémas dessinés (préalable) par vous même, le sujet traité par l'équipe. Si l'exposé est jugé satisfaisant, le coefficient sera parté à 1.0.